Article Sidebar

PDF
Date Published: 22/08/2022
Abstract Views: 201
Views PDF: 156
DOI: https://doi.org/10.51298/vmj.v517i1.3139
Issue
Vol. 517 No. 1 (2022)
Section
Các bài báo
How to Cite
Thành Vinh, T. ., Vĩnh Niên, L. ., Văn Thanh, L. ., Hữu Hoàng, . L. ., Thị Kim Ái, L. ., Thị Anh Thư, P. ., & Hà Khánh Linh, D. . (2022). A SURVEY OF ANTI-SARS-COV-2 ANTIBODY LEVELS IN ADULT SERUM AFTER THE SECOND DOSE OF SARS-COV-2 VACCINS AT CHO RAY HOSPITAL. Vietnam Medical Journal, 517(1). https://doi.org/10.51298/vmj.v517i1.3139

A SURVEY OF ANTI-SARS-COV-2 ANTIBODY LEVELS IN ADULT SERUM AFTER THE SECOND DOSE OF SARS-COV-2 VACCINS AT CHO RAY HOSPITAL

Trần Thành Vinh1, Lâm Vĩnh Niên2, Lê Văn Thanh1, Lê Hữu Hoàng1, Lê Thị Kim Ái1, Phan Thị Anh Thư1, Dương Hà Khánh Linh1,
1 Cho Ray Hospital
2 University of Medicine and Pharmacy at Ho Chi Minh City

Main Article Content

Abstract

Background: Adequate vaccination has been shown to protect the community against COVID-19, the most important tool to prevent the COVID-19 pandemic. Objective: Investigation of anti-SARS-CoV-2 antibody levels after two doses of COVID-19 vaccine. Subjects and Methods: A descriptive cross-sectional study performed the first quantitative test for anti-SARS-CoV-2 antibodies in 332 and second in 196 adult volunteers. Comparison of antibody levels at 2-8 weeks and 8-14 weeks after vaccination with two vaccines AZD1222 or BNT162b2. Results: The antibody levels of AZD1222, BNT162b2, mix-and-match group and the total at 2-8 weeks after the second dose were 989 (476-1945), 1955 (1327-3245), 4368 (2066-6716) and 1622 (684- 3741) BAU/mL; at 8-14 weeks were 796 (385-1460), 1080 (848-1985), 1714 (1058-2647) and 1014 (490-1892) BAU/mL. Antibody level at 8-14 weeks was significantly lower than at 2-8 weeks after the second dose in all groups. There was no correlation between antibody levels with age, gender, weight and BMI in the studied groups. Conclusions: Vaccines AZD1222, BNT162b2 and mixed injection produce good antibodies. Antibody levels decreased significantly at 8-14 weeks compared with 2-8 weeks after the second dose.

Article Details

Keywords

Anti-SARS-CoV-2, vaccin AZD1222, vaccin BNT162b2

References

1. Bộ Y Tế (2021), Tình hình dịch bệnh Covid-19 Việt Nam/Thế Giới, Việt Nam, 19/10/2021, web https://covid19.gov.vn/.
2. S. K. Mishra (2021), "Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study", Cureus. 13(11), e19879.
3. S. A. Madhi (2021), "Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial", Lancet HIV. 8(9), e568-e580.
4. P. Naaber (2021), "Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study", Lancet Reg Health Eur. 10, 100208.
5. E. Terpos (2022), "Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222", Biomedicines. 10(2).
6. E. Terpos (2021), "Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?", Am J Hematol. 96(9), E321-E324.
7. A. Massarweh (2021), "Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer", JAMA Oncol. 7(8), 1133-1140.
8. E. G. Levin (2021), "Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months", N Engl J Med. 385(24), e84.